Regulators will continue to evaluate a possible link by reviewing meta-analysis of clinical trials across all GLP-1 products and analyzing postmarketing data in the Sentinel System.
A preliminary FDA review of GLP-1 drugs used to treat patients with type 2 diabetes or obesity finds there is no evidence they cause suicidal thoughts or actions, regulators said in a safety communication. But because the risk cannot be ruled out, regulators will continue to evaluate these drugs.
Regulators have over the last few months reviewed the reports of suicidal thoughts or actions received in the FDA Adverse Event Reporting System (FAERS) related to these drugs. (See below for list of drugs that have evaluated for this risk.) Because the information provided was often limited and because these events can be influenced by other potential factors, regulators said there wasn’t a clear link with the use of GLP-1.
They also reviewed results of clinical trials, including large outcome studies and observational studies and did not find an association between use of GLP-1 and the occurrence of suicidal thoughts or actions.
Regulators will conduct additional evaluations, including of meta-analysis of clinical trials across all GLP-1 products and also analyze postmarketing data in the Sentinel System. Sentinel is a large data network that contains health insurance claims and patient health records.
FDA-Approved GLP-1 Drugs
Source: FDA
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More